MNKD News 9.56 07/24/2014 05:27:51 Mannkind Corp (MNKD)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Mannkind Corp (MNKD) 9.56 $MNKD

3 Longtime Losers About to See Green?
Keith Speights, The Motley Fool - Motley Fool - Tue Jul 22, 4:00PM CDT
Imagine running a business that loses money every year for more than a decade. Now, imagine those losses combined total into the hundreds of millions -- even billions -- of dollars.  If you're Al Mann with MannKind , John Scarlett with Geron ,...

MannKind Up 29.2% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 21, 4:53PM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 4 months, MannKind has returned 29.18% as of today's recent price of $9.63.

Critical Alerts For MannKind, CVS Caremark, Express Scripts, Cheniere Energy, and HomeAway Released By InvestorsObserver
PR Newswire - Mon Jul 21, 8:31AM CDT
InvestorsObserver issues critical PriceWatch Alerts for MNKD, CVS, ESRX, LNG, and AWAY.

Top Swing Trade Ideas for Monday July 21: Cliffs Natural Resources, MannKind, PolyOne
at The Street - Mon Jul 21, 8:19AM CDT
Here are some technical guidelines that you may be able to profit from.

Yellen, Icahn Comments Put a Lid on Small-Cap Stocks, May Hurt Larger Market
at The Street - Wed Jul 16, 10:40AM CDT
Recent comments by Fed Chair Janet Yellen and activist investor Carl Icahn have led to selling pressure in small-cap stocks.

Stock Market Today: Social Media, Biotech Suffer as Janet Yellen Shares Concerns on Valuation
at The Street - Tue Jul 15, 3:19PM CDT
Major indices trembled and the Nasdaq slid Tuesday following Fed Chair Janet Yellen's remarks on biotech and social media valuations.

Fed Chair Yellen Says Small Biotech Stocks Over-Valued
at The Street - Tue Jul 15, 12:10PM CDT
Biotech indices plunge on cautious remarks made by Fed Chairwoman during Congressional testimony.

MannKind Up 35.1% Since SmarTrend Uptrend Call (MNKD)
Comtex SmarTrend(R) - Mon Jul 14, 11:02AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.08% as of today's recent price of $10.07.

Biotech Stock Mailbag: MannKind, Bluebird, Northwest Bio, More '14 Tradable Biotech Events
at The Street - Mon Jul 14, 8:30AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Stocks to Watch This Week
Rick Munarriz, The Motley Fool - Motley Fool - Sat Jul 12, 9:00AM CDT
There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come. Monday Peregrine Pharmaceuticals   kicks off the new trading week with its latest quarterly report on Monday afternoon. Peregrine is...

SmarTrend Watching for Potential Pullback in Shares of MannKind After 1.82% Gain
Comtex SmarTrend(R) - Fri Jul 11, 5:24PM CDT
MannKind (NASDAQ:MNKD) traded in a range yesterday that spanned from a low of $9.81 to a high of $10.10. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $9.98 on volume of 5.0 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Is This MannKind's Greatest Risk?
Keith Speights, The Motley Fool - Motley Fool - Fri Jul 11, 4:00PM CDT
Not long ago, some predicted that MannKind faced the serious risk of striking out on winning approval for Afrezza. Instead, those predictions swung and missed. The U.S. Food and Drug Administration recently approved the inhaled insulin. With...

14 Insanely Important Biotech/Drug Trading Catalysts for the Rest of 2014
at The Street - Thu Jul 10, 10:54AM CDT
Healthcare investors (and traders) have had a lot to work with so far this year, and the next six months promises to be equally action packed.

MannKind Shares Up 35.3% Since SmarTrend's Buy Recommendation (MNKD)
Comtex SmarTrend(R) - Mon Jul 07, 9:37AM CDT
SmarTrend identified an Uptrend for MannKind (NASDAQ:MNKD) on April 2nd, 2014 at $7.46. In approximately 3 months, MannKind has returned 35.35% as of today's recent price of $10.09.

3 Things to Look for in MannKind's Partnership
Brian Orelli, The Motley Fool - Motley Fool - Fri Jul 04, 4:00PM CDT
It's been a week since MannKind gained Food and Drug Administration approval for its inhaled insulin Afrezza, and the biotech still hasn't announced a marketing partner. What's taking so long? I jest. But I'm allowed to. MannKind has been...

NDA Submission, Results Release Schedules, FDA Grants and Approvals, and Agreements - Analyst Notes on Gilead, Biogen Idec, Amgen, Illumina and MannKind
PR Newswire - Fri Jul 04, 4:20AM CDT
Today, Analysts Review released its analysts' notes regarding Gilead Sciences, Inc. (NASDAQ: GILD), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Illumina, Inc. (NASDAQ: ILMN) and MannKind Corporation (NASDAQ: MNKD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/4444-100free.

Most active Nasdaq-traded stocks
AP - Thu Jul 03, 4:15PM CDT
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:

MannKind Corp Analyst Report; Afrezza is Approved and Future Developments by BrokerBank Securities, Inc.
PR Newswire - Thu Jul 03, 10:15AM CDT
MannKind Corporation (NASDAQ: MNKD) is a biopharmaceutical company focused on the discovery and development of therapeutic products for diseases such as diabetes. The company's lead product - Afrezza inhalation powder - was recently approved by the FDA as a rapid-acting insulin therapy intended to improve glycemic control in adults with type 1 or type 2 diabetes. MannKind was founded by Al Mann for the purpose of developing inhaled insulin as an alternative to traditional injected insulin.

Biotech Stocks to Watch Today: AbbVie, Bind Therapeutics, MannKind, and Shire
George Budwell, The Motley Fool - Motley Fool - Thu Jul 03, 7:42AM CDT
Let's take a look at today's top stories in biotech and health care. Keep an eye out for AbbVie , Bind Therapeutics ,  MannKind Corp. and Shire .  AbbVie still pursuing Shire  Despite three rejections so far, AbbVie is reportedly still...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mercari and Suruga-ya Forge U.S. Venture for Culture

Updated Category News Views 0

Japanese Pop Culture Gears Up for US Market Surge Alright, folks, what we’ve got here is another bold move in the cross-border e-commerce game. Mercari and Suruga-ya are teaming up to establish a joint venture over in the U.S. The goal? To further capitalize on the growing appetite for Japanese entertainment and hobby goods among us all stateside. Now, it’s no secret...

Continue Reading
Tuya Smart: AI Powers New Energy Wave at COP31

Updated Category News Views 55

Tuya Smart's Bold Move at COP31 Tuya Smart, a name you don't want to ignore in the world of energy innovation, made a commanding appearance at COP31. Their message was loud and clear: as the climate gets harsher, they're not just sitting around waiting for the next storm. They're arming households with AI-driven solutions. AI-Powered Energy Management Takes Center Stage...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 229

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 64

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 71

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 218

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 175

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 178

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading

Top 5 Most Recently Viewed Articles

Balavant Insurance Group Welcomes John Jankowski as CIO

Updated Category News Views 317

Leadership Appointment at Balavant Insurance Group Balavant Insurance Group has made a significant move by appointing John Jankowski as its new Chief Information Officer. This announcement marks a pivotal moment for the company, known for its focus on technological advancement and innovative insurance solutions. Strategic Role of the Chief Information Officer In his role,...

Continue Reading
Exploring the Growth of the Industrial Absorbent Sector

Updated Category News Views 245

Understanding the Industrial Absorbent Market Dynamics The industrial absorbent market is poised for remarkable growth, expected to reach $5.50 billion by 2031. This growth trajectory aligns with a compound annual growth rate (CAGR) of 4.3%. The increase in market size is largely driven by the rising usage of absorbents across various industries in response to...

Continue Reading
ChoiceOne Financial Services Achieves Successful Bank Merger

Updated Category News Views 147

Successful Bank Merger by ChoiceOne Financial Services ChoiceOne Financial Services, Inc. (NASDAQ: COFS), the parent company of ChoiceOne Bank, has achieved a significant milestone by completing the consolidation of The State Bank into ChoiceOne Bank. This strategic move empowers the strength of ChoiceOne, further enhancing its service capabilities and market presence. A...

Continue Reading
Danantara Indonesia and INA Forge Nickel Investment Alliance with Eramet

Updated Category News Views 443

Strategic Collaboration for Nickel Development In a significant move to bolster the nickel downstream industry, partners including Danantara Indonesia and the Indonesia Investment Authority (INA) have officially signed a Memorandum of Understanding (MoU) with the prominent French mining company, Eramet. This collaboration aims to create an extensive investment platform...

Continue Reading
Full Moon Bar-B-Que's Generous Initiative for Local Kids

Updated Category News Views 180

Full Moon Bar-B-Que's Generosity In a heartwarming gesture, Full Moon Bar-B-Que has made a significant impact on the community by contributing $200,000 worth of backpacks and school supplies. Their ongoing commitment through the Backpack Blessings program is not just about donations; it's about nurturing and empowering local children who need support the most. Supporting...

Continue Reading